BioStem Technologies, Inc.
BSEMBioStem Technologies, Inc. in brief
BioStem Technologies, Inc. is a listed company in the Biotechnology industry, based in Pompano Beach, Florida, USA. Its market value was $29 M on 29 October 2026, which makes it the 23,195th largest listed company in the world and the 4,052nd largest in the USA on this site. In the year to December 2025 it had sales of $47 M and a net loss of $7 M. Jason Matuszewski is its chief executive. Its shares trade under the symbol BSEM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
BioStem Technologies, Inc. timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of BioStem Technologies, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,413 (Jan 2020) · #4,335 (Jan 2021) · #5,641 (Jan 2022) · #5,056 (Dec 2022) · #5,093 (Jul 2023) · #3,688 (Aug 2026) · #3,896 (Oct 2026) · #4,055 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.7×
- Price / book
- 0.7×
- Free cash flow yield
- 22.8%
- Net margin (TTM)
- -66.6%
- Operating margin
- -1.5%
- Return on equity
- -70.8%
- Liabilities / assets
- 21.8%
- Net debt
- $-30M
- Revenue growth
- -31.8%
- R&D / revenue
- 14.9%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $47M | -31.8% | $-1M | $-7M | -13.9% |
| Dec 2024 | $70M | — | $31M | $31M | 44.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $10M | $3M | $7M | $-0.39 | — |
| Dec 2024 | $24M | $0M | $24M | $1.43 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $8M (-27.0% on a year earlier), net income $-11M. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 2, 2026S-1IPO registration
- Sep 30, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure · Other events
- Sep 18, 2026S-1IPO registration
- Sep 18, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- Aug 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 7, 2026S-1/AIPO registration (amended)
- Aug 7, 20268-KCurrent reportOther events
- Jul 29, 2026S-1IPO registration
Official filings of BioStem Technologies, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $47 M
- Operating income
- $-1 M
- Net income
- $-7 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $50 M
- Total liabilities
- $11 M
- Total equity
- $39 M
As of December-2025
Top 26 institutional investors in BioStem Technologies, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | PNC Financial Services Group, Inc. | 543,847 | New | 2.84% | $2 M | Nov 6, 2026 |
| 2 | Vanguard Capital Management LLC | 484,811 | New | 2.53% | $1 M | Nov 13, 2026 |
| 3 | Anson Funds Management LP | 367,648 | New | 1.92% | $1 M | Nov 13, 2026 |
| 4 | Geode Capital Management, LLC | 141,388 | New | 0.74% | $0 M | Nov 6, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 81,753 | New | 0.43% | $0 M | Nov 13, 2026 |
| 6 | Northern Trust Corp | 33,421 | New | 0.17% | $0 M | Nov 16, 2026 |
| 7 | Millennium Management LLC | 23,990 | New | 0.13% | $0 M | Nov 16, 2026 |
| 8 | UBS Group AG | 19,969 | New | 0.10% | $0 M | Nov 10, 2026 |
| 9 | Virtu Financial LLC | 18,830 | New | 0.10% | $0 M | Nov 17, 2026 |
| 10 | StoneX Group Inc. | 18,251 | New | 0.10% | $0 M | Nov 3, 2026 |
| 11 | Elequin Capital, LP | 10,614 | New | 0.06% | $0 M | Nov 13, 2026 |
| 12 | Ashton Thomas Private Wealth, LLC | 10,078 | New | 0.05% | $0 M | Nov 3, 2026 |
| 13 | Vanguard Global Advisers, LLC | 6,961 | New | 0.04% | $0 M | Nov 13, 2026 |
| 14 | Beaird Harris Wealth Management, LLC | 2,000 | New | 0.01% | $0 M | Nov 13, 2026 |
| 15 | Osaic Holdings, Inc. | 1,550 | New | 0.01% | $0 M | Nov 12, 2026 |
| 16 | Tower Research Capital LLC (TRC) | 760 | New | 0.00% | $0 M | Nov 16, 2026 |
| 17 | Atlantic Union Bankshares Corp | 500 | New | 0.00% | $0 M | Nov 12, 2026 |
| 18 | Gables Capital Management Inc. | 350 | New | 0.00% | $0 M | Nov 4, 2026 |
| 19 | Wolff Wiese Magana LLC | 350 | New | 0.00% | $0 M | Oct 15, 2026 |
| 20 | HighMark Wealth Management LLC | 250 | New | 0.00% | $0 M | Nov 17, 2026 |
| 21 | Global Retirement Partners, LLC | 200 | New | 0.00% | $0 M | Nov 10, 2026 |
| 22 | Birchbrook, Inc. | 200 | New | 0.00% | $0 M | Oct 14, 2026 |
| 23 | FMR LLC | 100 | New | 0.00% | $0 M | Nov 10, 2026 |
| 24 | Jpmorgan Chase & Co | 79 | New | 0.00% | $0 M | Nov 12, 2026 |
| 25 | Allworth Financial LP | 74 | New | 0.00% | $0 M | Nov 17, 2026 |
Show all 26: investors 26 to 26
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Federation des caisses Desjardins du Quebec | 1 | New | 0.00% | $0 M | Nov 16, 2026 |
Insider trading at BioStem Technologies, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Brandon PoeChief Financial Officer | Option exercise | +2,699 | — | — | 60,763 | Form 4 |
| filed | Michael A. FortunatoChief Accounting Officer | Option exercise | +970 | — | — | 69,634 | Form 4 |
| filed | Barry HassettChief Commercial Officer | Option exercise | +253 | — | — | 5,256 | Form 4 |
| filed | Jason MatuszewskiChief Executive Officer, Director, 10% owner | Option exercise | +250,000 | $2.000 | $500 K | 1.55 M | Form 4 |
| filed | Vurst Andrew Smith-VanChief Operating Officer, Director, 10% owner | Option exercise | +250,000 | $2.000 | $500 K | 1.79 M | Form 4 |
| filed | Jason MatuszewskiChief Executive Officer, Director, 10% owner | Option exercise | +16,650 | — | — | 1.30 M | Form 4 |
| filed | Vurst Andrew Smith-VanChief Operating Officer, Director, 10% owner | Option exercise | +9,574 | — | — | 1.54 M | Form 4 |
| filed | Jason MatuszewskiChief Executive Officer, Director, 10% owner | Option exercise | +8,469 | — | — | 1.29 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: BioStem Technologies, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: registered (S-1), not yet priced · IPO calendar
Trading halts
- 2026-08-13 13:30 UTC, code LUDP, resumed 13:35 UTC
Fails to deliver
- : 9 shares at $1.51
- : 188,086 shares at $1.54
- : 140,882 shares at $1.57
- : 109,141 shares at $1.66
- : 102,141 shares at $1.68
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
BioStem Technologies, Inc. scorecard#
Passes 9 of the 15 checks that could be worked out: strongest in financial health (4 of 4), weakest in profitability (1 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation3 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median0.7×Price to sales 0.7× against Biotechnology's median of 8.7×.
- ✓Free cash flow yield above 5%22.8%Free cash flow is 22.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'No revenue growth over three years on file.
Growth0 of 2
- ✗Revenue grew in the newest year-31.8%Revenue down 31.8% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.39 vs 1.43Diluted EPS -0.39 in fiscal 2025 against 1.43 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 3
- ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✓Operating margin above its peers' median-1.4%-1.4% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-16.6%-16.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health4 of 4
- ✓Short-term assets cover short-term liabilities4.1×Current ratio 4.12 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $30 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- ✓Altman Z-score outside the distress zone2.71Z-score 2.71 (grey zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-22.9%Diluted shares down 22.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from BioStem Technologies, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -1.5% | -60.5% | |
| Net margin | -13.9% | -68.9% | |
| Return on equity | -16.6% | -61.0% | |
| Revenue growth | -31.8% | 15.8% | |
| Debt to equity | 0.00× | 0.26× | |
| Free cash flow margin | 13.9% | -61.5% |
5of 9on the Piotroski tests of financial strength
- Revenue fell 31.8% against the year before.
- Net loss of $7 million.
- The share count fell 22.9% in the year (buybacks).
- More cash than debt: net cash of $30 million.
Events at BioStem Technologies, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Material agreement 2 · Unregistered share sale 2 · Results announced 2
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by BioStem Technologies, Inc.#
$430 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.
- Medicare/Medicaid4 reports
Lobbying firms hired in 2025
BALLARD PARTNERS $430 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $180 K | — | 2 |
| 2025 | $430 K | — | 4 |
| 2024 | $160 K | — | 2 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “BioStem Technologies”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How BioStem Technologies, Inc. compares in Biotechnology
- Market cap$29 M · higher than 21% of 726
- Revenue$47 M · higher than 59% of 647
- Net margin-66.6% · higher than 48% of 408
- Revenue growth-31.8% · higher than 26% of 438
- Price / sales0.7× · lower than 96% of 339
- Price / book0.7× · lower than 84% of 534
- FCF yield22.8% · higher than 99% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BioStem Technologies, Inc.🇺🇸 | $29 M | — | -66.6% | -31.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BioStem Technologies, Inc.? Verify and update this profile — free
Show BioStem Technologies, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.